Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory...

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Atherosclerosis Research

Background:

• Reducing low-density lipoprotein cholesterol (LDLc) improves survival by 20-30% in patients with pre-existing vascular disease.
• Established atherosclerotic vascular disease (AVD) is largely irreversible with current therapies.
• Other factors beyond LDLc contribute to AVD, including the atherogenic lipoprotein phenotype (ALP).

Purpose of the Study:

• To review the mechanisms linking the atherogenic lipoprotein phenotype (ALP) to atherosclerotic vascular disease (AVD).
• To explore how triglyceride-rich lipoproteins contribute to AVD.
• To discuss the role of ALP in platelet function, coagulation, and vascular inflammation.

Main Methods:

• Review of existing angiographic studies.
• Analysis of recent evidence on procoagulant and proinflammatory states.
• Discussion of proposed mechanisms linking ALP to AVD.

Main Results:

• Established atherosclerotic vascular disease (AVD) is often irreversible.
• The atherogenic lipoprotein phenotype (ALP), characterized by lipoprotein abnormalities, is a significant risk factor for AVD.
• The precise mechanisms linking ALP to AVD are not fully understood but may involve procoagulant and proinflammatory pathways.

Conclusions:

• Current LDLc-lowering therapies have limitations in fully reversing established atherosclerotic vascular disease (AVD).
• The atherogenic lipoprotein phenotype (ALP) plays a crucial role in AVD development.
• Further research is needed to elucidate how ALP, particularly triglyceride-rich lipoproteins, impacts vascular health via platelet function, coagulation, and inflammation.